Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

1.645 +0.075 (+4.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Shares of Symbotic Inc. (NASDAQ: SYM) surged in pre-market trading after the company reported better-than-expected fourth-quarter sales results. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
EXCLUSIVE: Alzamend Neuro Receives FDA Go-Ahead Letter For Mid-Stage Major Depressive Disorder Study
Alzamend Neuro Inc (NASDAQ: ALZN) has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01, a Phase 2A clinical study of AL001 for  
Via Benzinga
Exposures Product Safety
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Seeks FDA Approval For Mid-Stage PTSD Study With Next‑Gen Lithium Therapeutic Drug Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA for the initiation of study AL001-PTSD01, a Phase 2A plasma/brain pharmacokinetics study of... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Dow Surges Over 500 Points; Western Digital Announces Plan To Split Into Two Companies
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday. The Dow traded up 1.67% to 32,959.68 while the NASDAQ rose 1.25% to 12,800.95. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
From Alzamend Neuro, Inc.
Via Business Wire
Crude Oil Falls Over 3%; Miromatrix Medical Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.14% to 32,788.73 while the NASDAQ rose 0.98% to 12,766.33. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. 
Via Benzinga
Why Alzamend Neuro (ALZN) Stock Is Nosediving Today
Alzamend Neuro Inc (NASDAQ: ALZN) shares are trading lower by 31.2% to $0.12 Monday morning after the company announced a reverse stock split. What Happened? 
Via Benzinga
Nasdaq Gains Over 1%; McDonald's Reports Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday. Following the market opening Monday, the Dow traded up 0.85% to 32,695.89 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Announces Reverse Stock Split
From Alzamend Neuro, Inc.
Via Business Wire
EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for... 
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1.  The company expects the... 
Via Benzinga
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
From Alzamend Neuro, Inc.
Via Business Wire
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
From Alzamend Neuro
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro
Via Business Wire
EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.  
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.